A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...

This indepth analysis categorizes OTC products by pharmaceutical drugs, vitamin and mineral supplements and various devices and diagnostics for disease management, including monitoring, therapeutic ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the third quarter of fiscal 2025 were $2.37, up 11.3% year over year.

With the launch of the Distributed Super-Sensing Module, Huawei returns to the top of the wearable market in top form ...

Morgans senior healthcare analyst Scott Power says healthcare stocks have had a strong start to the latest reporting season.

After reporting robust results, Resmed reckons it won't be subject to US tariffs while the growth of anti-obesity drugs will be a tailwind.

The indoor air quality landscape of 2025 is more complex than ever before, with a mix of challenges and opportunities.

This Home Assistant custom integration utilizes the anker-solix Python library, allowing seamless integration with Anker Solix devices via the Anker power cloud. It was specifically developed to ...

Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs ...